Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria

•Most hemolysis events in difficult-to-treat patients with PNH on pegcetacoplan were manageable without pegcetacoplan discontinuation.•Higher disease activity at baseline may indicate patients at increased risk of hemolysis.